grown exponentially in the last 20 years," but it's still small and vulnerable, says Roberto Mayor, a Chilean developmental biologist at University College London. "The effect will be amplified," predicts Mayor, who is trying to raise funds to help. María Elena Boisier Pons, president of CONICYT, Chile's science funding agency, says, "We'll need as a country to reconstruct our labs and our science."
A tsunami that followed the quake also wreaked havoc, killing a researcher involved in an ecology expedition to Robinson Crusoe Island off Chile's coast. Ecologist Álvaro Palma of Pontifical Catholic University of Chile in Santiago, who had dispatched the team of five to the island, says the group scrambled uphill from their house near shore to escape the wall of water. But Paula Ayerdi, a 28-yearold research assistant in marine biology, became separated. Her body was found along the shore the next day.
The wave also gutted a marine research station operated by the University of Concepción in Dichato, a fishing town about 50 kilometers from the city, and left its research vessel, the Kay-Kay, stranded half a mile from shore, according to Carola Espinoza, a marine biologist at the university. "Our laboratory was totally destroyed by the tsunami. It's turned upside down and full of sediment and algae," Espinoza says. Washed away were marine samples dating from the 1960s, aquariums used in breeding experiments, the station's library, and microscopes and other valuable equipment.
The university's oceanography program at Dichato and on the main campus in Concepción is "very strong" and attracted many collaborators from the United States and Europe to study a region of upwelling and high productivity off the Chilean coast, says Daniel Repeta, a marine chemist at Woods Hole Oceanographic Institution in Massachusetts. "I'm sure it's a big setback," says Repeta, who visited Dichato several years ago.
Farther north at the University of Chile in Santiago, the earthquake severely shook the modern four-story Millennium building that houses biology labs, toppling glassware, microscopes, incubators, PCR machines, and refrigerators. A flood from a broken water pipe on the top floor www.sciencemag.org SCIENCE VOL 327 12 MARCH 2010
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Mining NASA's "lost" data 1322 and an electricity shutoff added to the damage, says Miguel Allende, who heads a cell genomics center in the building.
Researchers rushed to their labs the morning after the quake to slosh through chemical-laced water and salvage cell cultures and other frozen samples and reagents. But many materials were lost, Allende says.
About half of the biology department's 40 or so research groups suffered losses from the quake, says department chair Ana Preller. "The big problem is equipment," Preller says. Her preliminary estimate is $600,000 in losses. The quake also shifted and may have damaged a cyclotron in the physics department.
Allende and other faculty members have sent some students to colleagues' labs for now. Colleagues abroad have also offered to take in students from Concepción and Santiago. "It's taken 11 years to get where I am now. Doing science here is very hard. It's discouraging. But maybe it will be an opportunity to do some new things," Allende says.
-JOCELYN KAISER AND ANTONIO REGALADO The results were remarkable: The 2008 Lancet study, a double-blind, placebo-controlled trial, reported that 89 people with mild to moderate Alzheimer's disease who took Dimebon showed significant improvements in memory and cognition, as well as the ability to carry out the activities of daily life. The effects far surpassed those of any Alzheimer's drug on the market or in development, and Hung says several pharmaceutical companies bid to purchase the rights to Dimebon. Pfizer won, paying $225 million.
The Lancet findings struck many researchers as too good to be true, says Rudolph Tanzi, an Alzheimer's researcher at Harvard University. "Nobody could figure out what an antihistamine does" to fight Alzheimer's disease, says Sam Sisodia of the University of Chicago in Illinois. Several ideas have been floated, Sisodia says, but supporting evidence is scant. Still, he and others say they were willing to suspend their disbelief, largely because of the involvement of Aisen, Doody, and Sano. "If you had to pick the five best trialists in the world, they would be three of them," Gandy says.
But the new trial, despite a design almost identical to that of the Lancet study, yielded dramatically different results. It enrolled 598 patients with mild to moderate Alzheimer's. This time, however, there were no significant differences between the Dimebon and placebo groups. "It's hugely disappointing," says Aisen. He says he's at a loss to explain the discrepancy, although he notes that it's not unheard of for a drug to have both positive and negative trials before winning approval. Gandy, however, says, "I'm not sure that there has ever been such a night-and-day difference in replicate trials that turned out to be biological variation." Medivation and Pfizer are poring over the data in search of an explanation, says Hung, who declined to discuss their leading hypotheses. For now, the companies will continue with three other Dimebon trials already under way for Alzheimer's disease, in addition to one for Huntington's disease.
But to some, Dimebon is starting to look like a dark horse whose race is run. "I don't think that the drug is dead and buried today, but we need to get some clarity or good news soon," Gandy says.
-GREG MILLER
The Puzzling Rise and Fall of a Dark-Horse Alzheimer's Drug PHARMACOLOGY Bad news. A recent trial dims hopes that Dimebon will be an effective treatment for Alzheimer's disease, which loads the brain with amyloid plaques (right).
